Filing Flows › BeOne Medicines (ONC) › How it makes money
How BeOne Medicines (ONC) makes money
BeOne Medicines (ONC) made $1.9B of revenue in the third quarter 2026 (Q3 2026), +34% from a year earlier. Product revenue, net brought in $1.9B (98%); BAITUOWEI brought in $22.1M (1%); POBEVCY brought in $10.7M (1%). Of every dollar of revenue, 89¢ was left as gross profit, 22¢ was left as operating profit, 20¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Product revenue, net | $1.9B | 98.3% | — | +34% |
| ↳ BRUKINSA | $1.4B | 73.6% | — | +34% |
| ↳ TEVIMBRA | $243M | 12.9% | — | +28% |
| ↳ XGEVA | $105M | 5.6% | — | +25% |
| ↳ BLINCYTO | $38.9M | 2.1% | — | +28% |
| ↳ Other Revenue | $34.8M | 1.8% | — | +101% |
| ↳ Other | $29.8M | 1.6% | — | +236% |
| ↳ KYPROLIS | $13.9M | 0.7% | — | -24% |
| BAITUOWEI | $22.1M | 1.2% | — | +97% |
| POBEVCY | $10.7M | 0.6% | — | +2% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $1.9B | 100.0% |
| Cost of revenue | $217M | 11.5% |
| Gross profit | $1.7B | 88.5% |
| Operating expenses | $1.3B | 66.4% |
| Operating profit | $419M | 22.2% |
| Income tax | $25.7M | 1.4% |
| Net earnings | $385M | 20.4% |
| Operating cash flow | $509M | 26.9% |
| Free cash flow | $474M | 25.1% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $1.9B | +34% |
| Q2 2026 | $1.7B | +30% |
| Q1 2026 | $1.5B | +36% |
| Q4 2025 | $1.5B | +33% |
| Q3 2025 | $1.4B | +41% |
| Q2 2025 | $1.3B | +42% |
| Q1 2025 | $1.1B | +49% |
From BeOne Medicines' 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does BeOne Medicines make money?
BeOne Medicines (ONC) made $1.9B of revenue in the third quarter 2026 (Q3 2026), +34% from a year earlier. Product revenue, net brought in $1.9B (98%); BAITUOWEI brought in $22.1M (1%); POBEVCY brought in $10.7M (1%). Of every dollar of revenue, 89¢ was left as gross profit, 22¢ was left as operating profit, 20¢ was left as net earnings.
What is BeOne Medicines' biggest business?
Product revenue, net: $1.9B in the third quarter 2026, 98% of revenue, +34% from a year earlier.
What is BeOne Medicines' profit margin?
Net earnings were $385M, 20.4% of revenue, in the third quarter 2026; the operating margin was 22.2%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.